Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
AssigneesOtonomy, Inc., The Regents of the University of California
InventorsJay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
Claims20
An otic composition for intratympanic administration comprising:
- a) an active agent;
- and
- b) from about 10% to about 40% by weight of a polyoxyethylene-polyoxypropylene triblock copolymer;
- wherein the active agent is from about 2% to about 15% by weight of valproic acid or sodium valproate, and
- wherein the active agent is not in the form of encapsulated particles,
- wherein the active agent is not in the form of nanoparticles, microspheres or microparticles, and wherein the composition has a gelation temperature from about 19° C. to about 37° C.
A method of treating an otic disease or condition comprising administering to an individual in need thereof an intratympanic composition comprising:
- a) an active agent;
- and
- b) from about 10% to about 40% by weight of a polyoxyethylene-polyoxypropylene triblock copolymer;
- wherein the active agent is from about 2% to about 15% by weight of valproic acid or sodium valproate, and
- wherein the active agent is not in the form of encapsulated particles,
- wherein the active agent is not in the form of nanoparticles, microspheres or microparticles, and wherein the composition has a gelation temperature from about 19° C. to about 37° C.
Dependencies are inferred from the claim text.